U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents…
Company generated approximately $2.8M of non-dilutive funding to extend cash runwayWESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech…
BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology…
NEWPORT BEACH, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce that it has entered a…
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously…
PLEASANTON, Calif.--(BUSINESS WIRE)--#Ophthalmology--RadiusXR, the trailblazer in Digital Health, announces the publication of its groundbreaking NOVA Clinical Trial in Translational Vision…
TORONTO, ON / ACCESSWIRE / March 25, 2024 / ProteinQure, the leading startup in the computational design of peptide drugs,…
Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc.…
Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows…
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and olderMALVERN, Pa.,…